Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Unifying mechanism for different fibrotic diseases.

Wernig G, Chen SY, Cui L, Van Neste C, Tsai JM, Kambham N, Vogel H, Natkunam Y, Gilliland DG, Nolan G, Weissman IL.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4757-4762. doi: 10.1073/pnas.1621375114. Epub 2017 Apr 19.

2.

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context.

Severyn B, Nguyen T, Altman MD, Li L, Nagashima K, Naumov GN, Sathyanarayanan S, Cook E, Morris E, Ferrer M, Arthur B, Benita Y, Watters J, Loboda A, Hermes J, Gilliland DG, Cleary MA, Carroll PM, Strack P, Tudor M, Andersen JN.

J Biomol Screen. 2016 Oct;21(9):989-97. doi: 10.1177/1087057116658646. Epub 2016 Jul 26.

PMID:
27461835
3.

Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells.

Cai X, Gao L, Teng L, Ge J, Oo ZM, Kumar AR, Gilliland DG, Mason PJ, Tan K, Speck NA.

Cell Stem Cell. 2015 Aug 6;17(2):165-77. doi: 10.1016/j.stem.2015.06.002. Epub 2015 Jul 9.

4.

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.

Taylor SJ, Thien CB, Dagger SA, Duyvestyn JM, Grove CS, Lee BH, Gilliland DG, Langdon WY.

Exp Hematol. 2015 Mar;43(3):191-206.e1. doi: 10.1016/j.exphem.2014.11.009. Epub 2014 Dec 19.

5.

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL.

Blood. 2014 May 29;123(22):e123-33. doi: 10.1182/blood-2014-02-554634. Epub 2014 Apr 16.

6.

Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MAS, Scadden DT, Schreiber SL, Ebert BL, Golub TR.

Nat Chem Biol. 2013 Dec;9(12):840-848. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27.

7.

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.

Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.

Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22.

8.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.

Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.

9.

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T.

Cancer Res. 2013 Jan 1;73(1):373-84. doi: 10.1158/0008-5472.CAN-12-0255. Epub 2012 Nov 13.

10.

mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.

Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA.

Cell Stem Cell. 2012 Sep 7;11(3):429-39. doi: 10.1016/j.stem.2012.06.009.

11.

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD.

Cell. 2012 Aug 3;150(3):575-89. doi: 10.1016/j.cell.2012.06.032.

12.

Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Rice KL, Lin X, Wolniak K, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P, Levine R, Golub T, Gilliland DG, Crispino JD, Licht JD, Zhang W.

Blood Cancer J. 2011 Nov;1(11):e40. doi: 10.1038/bcj.2011.39. Epub 2011 Nov 11.

13.

Drug development and clinical trials--the path to an approved cancer drug.

Rubin EH, Gilliland DG.

Nat Rev Clin Oncol. 2012 Feb 28;9(4):215-22. doi: 10.1038/nrclinonc.2012.22. Review.

PMID:
22371130
14.

A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells.

Liu J, Mercher T, Scholl C, Brumme K, Gilliland DG, Zhu N.

Exp Hematol. 2012 Jun;40(6):487-98.e3. doi: 10.1016/j.exphem.2012.01.017. Epub 2012 Feb 1.

PMID:
22306297
15.

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Zhao L, Melenhorst JJ, Alemu L, Kirby M, Anderson S, Kench M, Hoogstraten-Miller S, Brinster L, Kamikubo Y, Gilliland DG, Liu PP.

Blood. 2012 Feb 9;119(6):1511-21. doi: 10.1182/blood-2011-02-338210. Epub 2011 Dec 7.

16.

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG.

Leukemia. 2012 Apr;26(4):720-7. doi: 10.1038/leu.2011.261. Epub 2011 Oct 18.

PMID:
22005786
17.

AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.

Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT.

Cell. 2011 Sep 2;146(5):697-708. doi: 10.1016/j.cell.2011.07.032. Erratum in: Cell. 2011 Sep 30;147(1):247. Schöll, Claudia [corrected to Scholl, Claudia].

18.

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL.

Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.

19.

Differential niche and Wnt requirements during acute myeloid leukemia progression.

Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA.

Blood. 2011 Sep 8;118(10):2849-56. doi: 10.1182/blood-2011-03-345165. Epub 2011 Jul 15.

20.

Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification.

Cornejo MG, Mabialah V, Sykes SM, Khandan T, Lo Celso C, Lopez CK, Rivera-Muñoz P, Rameau P, Tothova Z, Aster JC, DePinho RA, Scadden DT, Gilliland DG, Mercher T.

Blood. 2011 Aug 4;118(5):1264-73. doi: 10.1182/blood-2011-01-328567. Epub 2011 Jun 7.

21.

Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.

Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, Gilliland DG, Huntly BJ.

Cancer Res. 2011 Jun 15;71(12):4117-29. doi: 10.1158/0008-5472.CAN-11-0176. Epub 2011 Apr 19.

22.

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, Beran M, Gilliland DG, Levine RL, Tefferi A.

Leukemia. 2011 Jul;25(7):1200-2. doi: 10.1038/leu.2011.58. Epub 2011 Apr 1. No abstract available.

23.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

24.

mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.

Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS, Gilliland DG, Morrison SJ.

Cell Stem Cell. 2010 Nov 5;7(5):593-605. doi: 10.1016/j.stem.2010.09.015.

25.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.

J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.

26.

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.

Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ.

Nat Med. 2010 Aug;16(8):903-8. doi: 10.1038/nm.2187. Epub 2010 Jul 8.

27.

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD.

Clin Cancer Res. 2010 Sep 1;16(17):4339-52. doi: 10.1158/1078-0432.CCR-10-1092. Epub 2010 Jul 2.

28.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.

29.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.

Leukemia. 2010 Jul;24(7):1302-9. doi: 10.1038/leu.2010.113. Epub 2010 May 27.

30.

Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1.

Parmar K, Kim J, Sykes SM, Shimamura A, Stuckert P, Zhu K, Hamilton A, Deloach MK, Kutok JL, Akashi K, Gilliland DG, D'andrea A.

Stem Cells. 2010 Jul;28(7):1186-95. doi: 10.1002/stem.437.

31.

Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis.

Koo S, Huntly BJ, Wang Y, Chen J, Brumme K, Ball B, McKinney-Freeman SL, Yabuuchi A, Scholl C, Bansal D, Zon LI, Fröhling S, Daley GQ, Gilliland DG, Mercher T.

Haematologica. 2010 Oct;95(10):1642-50. doi: 10.3324/haematol.2010.023168. Epub 2010 May 21.

32.

The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.

Lane SW, Sykes SM, Al-Shahrour F, Shterental S, Paktinat M, Lo Celso C, Jesneck JL, Ebert BL, Williams DA, Gilliland DG.

Blood. 2010 Apr 29;115(17):3489-97. doi: 10.1182/blood-2009-11-251728. Epub 2010 Mar 2. Erratum in: Blood. 2014 Jan 9;123(2):301.

33.

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP.

Blood. 2010 Apr 8;115(14):2882-90. doi: 10.1182/blood-2009-07-235119. Epub 2010 Jan 12.

34.

Leukemia stem cells.

Lane SW, Gilliland DG.

Semin Cancer Biol. 2010 Apr;20(2):71-6. doi: 10.1016/j.semcancer.2009.12.001. Epub 2009 Dec 22. Review.

PMID:
20026405
35.

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K.

Blood. 2010 Feb 18;115(7):1406-15. doi: 10.1182/blood-2009-06-229443. Epub 2009 Dec 14.

36.

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J.

Sci Signal. 2009 Nov 17;2(97):ra73. doi: 10.1126/scisignal.2000431.

37.

Direct inhibition of the NOTCH transcription factor complex.

Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE.

Nature. 2009 Nov 12;462(7270):182-8. doi: 10.1038/nature08543. Erratum in: Nature. 2010 Jan 21;463(7279):384.

38.

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC.

Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21.

39.

A progenitor cell origin of myeloid malignancies.

Haeno H, Levine RL, Gilliland DG, Michor F.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16616-21. doi: 10.1073/pnas.0908107106. Epub 2009 Sep 21.

40.

[The OTT-MAL fusion oncogene: another Notch in megakaryoblastic leukemia].

Bernard OA, Gilliland DG, Mercher T.

Med Sci (Paris). 2009 Aug-Sep;25(8-9):676-8. doi: 10.1051/medsci/2009258-9676. French. No abstract available.

41.

Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.

Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG.

Cell Stem Cell. 2009 Jun 5;4(6):559-67. doi: 10.1016/j.stem.2009.03.016.

42.

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG.

Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017.

43.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.

44.

The leukemic stem cell niche: current concepts and therapeutic opportunities.

Lane SW, Scadden DT, Gilliland DG.

Blood. 2009 Aug 6;114(6):1150-7. doi: 10.1182/blood-2009-01-202606. Epub 2009 Apr 28. Review.

45.

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.

Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT.

Leukemia. 2009 Sep;23(9):1605-13. doi: 10.1038/leu.2009.82. Epub 2009 Apr 23.

46.

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.

Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A, Tenen DG, Gilliland DG.

Leukemia. 2009 Aug;23(8):1462-71. doi: 10.1038/leu.2009.63. Epub 2009 Mar 26.

47.

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL.

Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19. No abstract available.

48.

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL.

Nat Genet. 2009 Apr;41(4):455-9. doi: 10.1038/ng.342. Epub 2009 Mar 15.

49.

The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.

Mercher T, Raffel GD, Moore SA, Cornejo MG, Baudry-Bluteau D, Cagnard N, Jesneck JL, Pikman Y, Cullen D, Williams IR, Akashi K, Shigematsu H, Bourquin JP, Giovannini M, Vainchenker W, Levine RL, Lee BH, Bernard OA, Gilliland DG.

J Clin Invest. 2009 Apr;119(4):852-64. doi: 10.1172/JCI35901. Epub 2009 Mar 16.

50.

A radical bailout strategy for cancer stem cells.

Tothova Z, Gilliland DG.

Cell Stem Cell. 2009 Mar 6;4(3):196-7. doi: 10.1016/j.stem.2009.02.008.

Supplemental Content

Loading ...
Support Center